Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 4, Issue 4, 1998, Pages 268-275

  Schulte, Claudia ^a   Dignass, Axel U ^a   Mann, Klaus ^a   Goebell, Harald ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Bone metabolism; Bone mineral density; Bone resorption; Inflammatory bowel disease; Osteopenia; Osteoporosis

Indexed keywords

ADULT; ANTHROPOMETRY; ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; ENTERITIS; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PROGNOSIS; RADIODENSITOMETRY; RISK FACTOR; ULCERATIVE COLITIS;

ADULT; ANTHROPOMETRY; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROGNOSIS; RISK FACTORS;

EID: 0032196476     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-199811000-00002     Document Type: Article

References (46)

1. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37: 1396-403.
2. Simberg N, Tiitinen A, Silfvast A, Viinikka L, Ylikorkala O. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogenprogestin replacement. J Clin Endocrinol Metab 1996;81:646-51.
3. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-15.
4. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a propective study. Osteoporos Int 1995;5:156-60.
5. Hessov I, Mosekilde L, Melsen F, et al. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastroenterol 1984;19:691-6.
6. Silvennoinen JA, Kartunnen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-6.
7. Nuti R, Martini G, Gennari C. Age-related changes of whole skeleton and body composition in healthy men. Calcif Tissue Int 1995; 57:336-9.
8. Cowan FJ, Parker DR, Jenkins UR. Ostopenia in Crohn's disease. Arch Dis Child 1995;73:255-6.
9. Neef B, Maier K-E, Gaisberg V. U Schwere Osteoporose bei einer jungen Patientin mit Morbus Crohn. Dtsch Med Wochenschr 1991; 116:1055-60.
10. Markowitz J, Daum F. Growth impairment in pediatric imflammatory bowel disease. Am J Gastroenterol 1994;89:319-26.
11. Dequeker J, Pearson J, Reeve J, et al. Dual X-ray absorptiometry - cross-calibration and normative reference ranges for the spine: results of a European community concerted action. Bone 1995;17: 247-54.
12. Faulkner KG, McClung MR. Quality control of DXA instruments in multicenter trials. Osteoporos Int 1995;5:218-27.
13. Glüer C-C, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK. Accurate assessment of precision errors: how to measure the reproducibility of bone densiometry techniques. Osteoporos Int 1995;5:262-70.
14. Compston JE, Cooper C, Kanis JA. Bone densiometry in clinical practice. BMJ 1995;310:1507-10.
15. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993; 77:1046-52.
16. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55:273-86.
17. Canalis E, McCarthy T, Centrella M. Growth Factors and the Regulation of Bone Remodeling. J Clin Invest 1988;81:277-81.
18. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991;303:961-4.
19. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects and osteoporosis patients. J Clin Endocrinol Metab 1995;80:2447-50.
20. Eastell R, Robins SP, Colwell T, Assiri AMA, Riggs BL, Russell RGG. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 1993;3:255-60.
21. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417-22.
22. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with bowel disease. Gut 1997;40:228-33.
23. Rachmilewitz D, DeSonzo SM. Coated mesalazine (5-aminosalicylic acid) versus sulphalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6.
24. Singleton JW, Kern F, Best WR, Becktel JM. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.
25. Kanis JA, WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO Report. Osteoporos Int 1994;4:368-81.
26. Windsor JA, Hill GL. Grip strength: a measure of the proportion of protein loss in surgical patients. Br J Surg 1988;75:880-2.
27. Seibel MJ. Hydroxy-Pyridinium "Crosslinks" im Urin als spezifische Marker der Knochenresorption bei metabolischen Knochenerkrankungen. Klin Lab Diagn 1992;38:642-3.
28. Robins SP, Woitge H, Hesley R, Ju J, Seydin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
29. Calabresi E, Lasagni L, Franceschelli F, et al. Comparison of immuno- and HPLC-assays for the measurement of urinary collagen cross-links. J Endocrinol Invest 1994;17:625-9.
30. Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
31. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Int Med 1990;112:352-64.
32. Sambrook PN, Jones G. Corticosteroid osteoporosis. Brit J Rheumatol 1995;34:8-12.
33. Scharla SH, Minne HW, Lempert UG, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol Diabetes 1994;102:44-9.
34. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983;35:410-17.
35. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-9.
36. Clements D, Motley RD, Evans WD, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-60.
37. Neef B, Künzig B, Gaisberg V. U. Osteopathie bei chronischendzündlicher Darmerkrankuna. Dtsch Med Wochenschr 1997; 122:195-9.
38. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995;10:641-9.
39. Rosen CJ, Chesnut III CH, Mallinak NJS. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
40. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994;78:955-9.
41. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700.
42. Chesnut III CH, Bell NH, Clark GF, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
43. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
44. Lukert BP. Etidronate in the management of glucocorticoid-induced osteoporosis. Am J Med 1995;99:233-4.
45. Eastell R. Management of corticosteroid-induced osteoporosis. J Intern Med 1995;237:439-47.
46. Hochberg MC. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39: 1791-1801.